1280 related articles for article (PubMed ID: 20887192)
21. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
[TBL] [Abstract][Full Text] [Related]
22. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.
Amann J; Kalyankrishna S; Massion PP; Ohm JE; Girard L; Shigematsu H; Peyton M; Juroske D; Huang Y; Stuart Salmon J; Kim YH; Pollack JR; Yanagisawa K; Gazdar A; Minna JD; Kurie JM; Carbone DP
Cancer Res; 2005 Jan; 65(1):226-35. PubMed ID: 15665299
[TBL] [Abstract][Full Text] [Related]
23. Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer.
Sun JM; Rampal S; Lee G; Lee J; Choi YL; Parasuraman B; Guallar E; Cho J; Shim YM
Lung Cancer; 2013 May; 80(2):191-6. PubMed ID: 23384673
[TBL] [Abstract][Full Text] [Related]
24. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.
Remon J; Morán T; Majem M; Reguart N; Dalmau E; Márquez-Medina D; Lianes P
Cancer Treat Rev; 2014 Feb; 40(1):93-101. PubMed ID: 23829935
[TBL] [Abstract][Full Text] [Related]
25. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Kobayashi S; Shimamura T; Monti S; Steidl U; Hetherington CJ; Lowell AM; Golub T; Meyerson M; Tenen DG; Shapiro GI; Halmos B
Cancer Res; 2006 Dec; 66(23):11389-98. PubMed ID: 17145885
[TBL] [Abstract][Full Text] [Related]
27. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
28. Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer.
Pennell NA
Clin Lung Cancer; 2011 Nov; 12(6):350-9. PubMed ID: 21723791
[TBL] [Abstract][Full Text] [Related]
29. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
30. EGFR mutation testing in non-small cell lung cancer (NSCLC).
Al Dayel F
J Infect Public Health; 2012 Dec; 5 Suppl 1():S31-4. PubMed ID: 23244184
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of EGFR mutation screening methods in non-small cell carcinoma of lung.
Gombos Z; Danihel L; Puttaswamy K; Brose M
Bratisl Lek Listy; 2010; 111(7):365-8. PubMed ID: 20806539
[TBL] [Abstract][Full Text] [Related]
32. MET: a new promising biomarker in non-small-cell lung carcinoma.
Pérez-Ramírez C; Cañadas-Garre M; Jiménez-Varo E; Faus-Dáder MJ; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(6):631-47. PubMed ID: 25893986
[TBL] [Abstract][Full Text] [Related]
33. Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma.
Prabhu VV; Devaraj N
J Environ Pathol Toxicol Oncol; 2017; 36(2):151-158. PubMed ID: 29199595
[TBL] [Abstract][Full Text] [Related]
34. Genetics and biomarkers in personalisation of lung cancer treatment.
Rosell R; Bivona TG; Karachaliou N
Lancet; 2013 Aug; 382(9893):720-31. PubMed ID: 23972815
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized.
Padrón D; Sato M; Shay JW; Gazdar AF; Minna JD; Roth MG
Cancer Res; 2007 Aug; 67(16):7695-702. PubMed ID: 17699773
[TBL] [Abstract][Full Text] [Related]
36. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
Malapelle U; Sirera R; Jantus-Lewintre E; Reclusa P; Calabuig-Fariñas S; Blasco A; Pisapia P; Rolfo C; Camps C
Expert Rev Mol Diagn; 2017 Mar; 17(3):209-215. PubMed ID: 28129709
[TBL] [Abstract][Full Text] [Related]
37. EGFR mutation testing for squamous cell lung carcinoma.
Liam CK; Leow HR; Pang YK
J Thorac Oncol; 2013 Dec; 8(12):e114. PubMed ID: 24389448
[No Abstract] [Full Text] [Related]
38. Recent clinical advances in lung cancer management.
Johnson DH; Schiller JH; Bunn PA
J Clin Oncol; 2014 Apr; 32(10):973-82. PubMed ID: 24567433
[TBL] [Abstract][Full Text] [Related]
39. Non-Small Cell Lung Cancer, Version 6.2015.
Ettinger DS; Wood DE; Akerley W; Bazhenova LA; Borghaei H; Camidge DR; Cheney RT; Chirieac LR; D'Amico TA; Demmy TL; Dilling TJ; Dobelbower MC; Govindan R; Grannis FW; Horn L; Jahan TM; Komaki R; Krug LM; Lackner RP; Lanuti M; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel JD; Pisters KM; Reckamp K; Riely GJ; Rohren E; Schild SE; Shapiro TA; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M;
J Natl Compr Canc Netw; 2015 May; 13(5):515-24. PubMed ID: 25964637
[TBL] [Abstract][Full Text] [Related]
40. EGFR gene mutations: is it prognostic or predictive in surgically resected lung cancer?
Mitsudomi T; Tada H
J Thorac Oncol; 2012 Dec; 7(12):1739-1741. PubMed ID: 23154542
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
